Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
22.33
Dollar change
+0.52
Percentage change
2.38
%
IndexRUT P/E- EPS (ttm)-15.34 Insider Own52.59% Shs Outstand8.29M Perf Week0.31%
Market Cap185.79M Forward P/E- EPS next Y-1.76 Insider Trans29.55% Shs Float3.94M Perf Month38.14%
Income-124.65M PEG- EPS next Q- Inst Own63.01% Short Float3.18% Perf Quarter79.09%
Sales0.00M P/S- EPS this Y-18.79% Inst Trans-1.20% Short Ratio2.03 Perf Half Y79.09%
Book/sh22.15 P/B1.01 EPS next Y88.50% ROA-48.85% Short Interest0.13M Perf Year84.94%
Cash/sh22.34 P/C1.00 EPS next 5Y25.90% ROE-51.95% 52W Range9.91 - 23.50 Perf YTD72.94%
Dividend Est.- P/FCF- EPS past 5Y-483.52% ROI-67.87% 52W High-4.98% Beta0.28
Dividend TTM0.00 (0.00%) Quick Ratio39.20 Sales past 5Y0.00% Gross Margin- 52W Low125.42% ATR (14)2.47
Dividend Ex-DateMar 15, 2024 Current Ratio39.20 EPS Y/Y TTM-17.72% Oper. Margin0.00% RSI (14)61.40 Volatility16.88% 11.59%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price28.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q10.50% Payout- Rel Volume2.48 Prev Close21.81
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume61.74K Price22.33
SMA2022.24% SMA5040.22% SMA20070.11% Trades Volume153,112 Change2.38%
Date Action Analyst Rating Change Price Target Change
Mar-27-24Initiated Piper Sandler Overweight $28
Feb-23-23Downgrade Cowen Outperform → Market Perform
Feb-23-23Downgrade Cantor Fitzgerald Overweight → Neutral $3
Feb-23-23Downgrade BofA Securities Neutral → Underperform $3 → $2
Jan-25-23Downgrade BTIG Research Buy → Neutral
Jan-18-23Downgrade BofA Securities Buy → Neutral $7 → $3
Jan-06-23Downgrade SVB Leerink Outperform → Mkt Perform $11 → $2
Jan-06-23Downgrade BMO Capital Markets Outperform → Market Perform $14 → $7
Sep-15-22Initiated Cantor Fitzgerald Overweight $12
Jun-17-22Initiated BMO Capital Markets Outperform $12
Mar-21-24 04:30PM
10:09AM
Mar-08-24 05:00PM
Mar-01-24 10:48AM
Feb-02-24 11:58AM
12:07PM Loading…
Jan-27-24 12:07PM
Nov-16-23 12:00PM
Nov-15-23 07:00AM
Jun-23-23 07:00AM
May-15-23 07:44AM
May-10-23 10:18AM
Apr-26-23 02:10PM
Mar-29-23 04:20PM
Mar-25-23 10:12AM
Mar-20-23 04:05PM
05:36PM Loading…
Feb-23-23 05:36PM
Feb-22-23 04:05PM
Jan-10-23 09:35AM
Jan-06-23 05:54PM
09:07AM
Jan-05-23 05:57PM
04:05PM
Dec-11-22 10:00AM
Nov-21-22 08:00AM
Nov-17-22 09:45AM
Nov-09-22 04:05PM
Nov-03-22 09:05AM
Oct-16-22 08:33AM
Oct-11-22 08:00AM
Sep-06-22 08:00AM
05:47PM Loading…
Aug-30-22 05:47PM
Aug-11-22 04:05PM
08:16AM
Jun-17-22 02:26PM
Jun-01-22 08:00AM
May-29-22 02:15PM
May-16-22 06:00AM
May-12-22 04:05PM
May-09-22 08:13AM
May-04-22 08:00AM
May-03-22 08:00AM
May-02-22 04:38PM
Mar-28-22 08:00AM
Mar-23-22 12:28PM
08:00AM
Mar-21-22 08:25AM
Mar-03-22 08:00AM
Mar-02-22 08:00AM
Feb-08-22 10:20AM
Jan-27-22 08:00AM
Jan-26-22 06:30PM
Dec-11-21 09:00AM
Dec-07-21 08:00AM
Nov-17-21 08:00AM
Nov-10-21 04:05PM
Nov-04-21 09:13AM
Oct-21-21 08:00AM
Oct-18-21 11:00AM
04:37AM
Oct-12-21 01:00PM
Oct-05-21 08:00AM
Sep-25-21 10:12AM
Aug-30-21 08:00AM
Aug-12-21 04:05PM
Jun-30-21 05:15PM
Jun-24-21 09:08PM
LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Del Mar, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorMar 21 '24Buy15.03998,00915,000,0753,319,339Mar 25 08:48 PM